Product Images Atorvastatin Calcium

View Photos of Packaging, Labels & Appearance

Product Label Images

The following 5 images provide visual information about the product associated with Atorvastatin Calcium NDC 68071-5237 by Nucare Pharmaceuticals,inc., such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.

pdp - 68071 5237 3

pdp - 68071 5237 3

This appears to be a product label for NuCare Pharmaceuticals, Inc. selling Atorvastatin Calcium 20mg tablets. The packaging includes lot number, serial number, and expiration date. It also provides a product code, manufacturer info, and contact information for medical advice. The label cautions to store at a controlled temperature and keep out of reach of children.*

Chemical Structure - atorvastatin calcium tablets 1

Chemical Structure - atorvastatin calcium tablets 1

Figure 1 - atorvastatin calcium tablets 2

Figure 1 - atorvastatin calcium tablets 2

The text seems to be presenting some statistical information about the cumulative incidence. There are numbers that seem to represent percentages, followed by the HR (Hazard Ratio) and its confidence interval, as well as the p-value. The numbers 20, 25, 30, and 35 might refer to the time in years. However, without further context or explanation, it is difficult to determine the meaning or significance of this information.*

Figure 2 - atorvastatin calcium tablets 3

Figure 2 - atorvastatin calcium tablets 3

The text describes a hazard analysis that shows the cumulative hazard percentage of an event over time. The given data shows the hazard percentages at two different time points, along with the hazard ratio and corresponding p-value. The analysis tracks the occurrence of a primary endpoint over a 4 year follow-up period.*

Figure 3 - atorvastatin calcium tablets 4

Figure 3 - atorvastatin calcium tablets 4

This text describes the percentage of subjects who experienced a major cardiovascular event while taking Atorvastatin 10 mg and 80 mg. It also includes the hazard ratio and statistical significance between the two doses. Additionally, there is a graph showing the time to the first major cardiovascular endpoint over a period of four years.*

* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.